Perigon Wealth Management LLC acquired a new position in shares of Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 85,185 shares of the company's stock, valued at approximately $509,000. Perigon Wealth Management LLC owned 0.27% of Sera Prognostics at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Frontier Wealth Management LLC acquired a new position in Sera Prognostics during the first quarter valued at approximately $30,000. Susquehanna International Group LLP bought a new stake in Sera Prognostics in the first quarter valued at approximately $39,000. Goldman Sachs Group Inc. bought a new stake in Sera Prognostics in the first quarter valued at approximately $41,000. Charles Schwab Investment Management Inc. bought a new stake in Sera Prognostics in the first quarter valued at approximately $46,000. Finally, Bank of New York Mellon Corp bought a new stake in Sera Prognostics in the first quarter valued at approximately $50,000. 54.64% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Sera Prognostics
In other news, insider Paul Kearney sold 4,984 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $8.03, for a total transaction of $40,021.52. Following the transaction, the insider now owns 160,066 shares in the company, valued at $1,285,329.98. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Paul Kearney sold 4,984 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $8.03, for a total transaction of $40,021.52. Following the sale, the insider now owns 160,066 shares of the company's stock, valued at $1,285,329.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Zhenya Lindgardt sold 38,899 shares of the stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $9.37, for a total value of $364,483.63. Following the sale, the chief executive officer now directly owns 908,104 shares in the company, valued at approximately $8,508,934.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 141,335 shares of company stock worth $1,255,192. Company insiders own 15.60% of the company's stock.
Sera Prognostics Trading Down 2.4 %
NASDAQ:SERA traded down $0.24 on Tuesday, hitting $9.80. The company's stock had a trading volume of 91,452 shares, compared to its average volume of 240,497. The stock has a fifty day moving average of $9.22 and a two-hundred day moving average of $5.80. The firm has a market capitalization of $317.81 million, a P/E ratio of -8.45 and a beta of 1.49. Sera Prognostics, Inc. has a one year low of $1.52 and a one year high of $11.32.
Sera Prognostics (NASDAQ:SERA - Get Free Report) last announced its earnings results on Wednesday, March 20th. The company reported ($0.25) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.25). The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million. Sera Prognostics had a negative return on equity of 45.74% and a negative net margin of 11,843.79%. As a group, sell-side analysts anticipate that Sera Prognostics, Inc. will post -0.94 EPS for the current year.
Sera Prognostics Company Profile
(
Free Report)
Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.
Further Reading
Before you consider Sera Prognostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sera Prognostics wasn't on the list.
While Sera Prognostics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
